Chagas Angelica de Lima das, Araújo Joilma Cruz da Silva, Serra Jaqueline Correia Pontes, Araújo Kelliane Martins de, Cunha Marcos de Oliveira, Correia Amanda Dos Reis, Gonçalves Laura Maria Barbosa, Carneiro Lilian Carla
Health Science Post Graduation, Federal University of Goias, Goiania 74605-050, Goias, Brazil.
Pharmacy Faculty, Federal University of Goias, Goiania 74605-170, Goias, Brazil.
Diagnostics (Basel). 2024 May 30;14(11):1149. doi: 10.3390/diagnostics14111149.
The study aimed to assess the prevalence of COVID-19 and spp. coinfection across continents. Conducted following PRISMA guidelines, a systematic review utilized PubMed, Embase, SCOPUS, ScienceDirect, and Web of Science databases, searching for literature in English published from December 2019 to December 2022, using specific Health Sciences descriptors. A total of 408 records were identified, but only 50 were eligible, and of these, only 33 were included. Thirty-three references were analyzed to evaluate the correlation between COVID-19 and spp. infections. The tabulated data represented a sample group of 8741 coinfected patients. The findings revealed notable disparities in co-infection rates across continents. In Asia, 23% of individuals were infected with , while in Europe, the proportion of co-infected patients stood at 15%. Strikingly, on the African continent, 43% were found to be infected with , highlighting significant regional variations. Overall, the proportion of co-infections among COVID-positive individuals were determined to be 19%. Particularly concerning was the observation that 1 in 6 ICU coinfections was attributed to , indicating its substantial impact on patient outcomes and healthcare burden. The study underscores the alarming prevalence of co-infection between COVID-19 and , potentially exacerbating the clinical severity of patients and posing challenges to treatment strategies. These findings emphasize the importance of vigilant surveillance and targeted interventions to mitigate the adverse effects of bacterial coinfections in the context of the COVID-19 pandemic.
该研究旨在评估新冠病毒与[某种细菌名称]在各大洲的合并感染率。按照PRISMA指南进行,一项系统综述利用了PubMed、Embase、SCOPUS、ScienceDirect和科学网数据库,使用特定的健康科学描述符搜索2019年12月至2022年12月发表的英文文献。共识别出408条记录,但只有50条符合条件,其中仅33条被纳入。对33篇参考文献进行分析,以评估新冠病毒与[某种细菌名称]感染之间的相关性。列表数据代表了8741名合并感染患者的样本组。研究结果显示各大洲的合并感染率存在显著差异。在亚洲,23%的个体感染了[某种细菌名称],而在欧洲,合并感染患者的比例为15%。令人惊讶的是,在非洲大陆,发现43%的人感染了[某种细菌名称],突出了显著的地区差异。总体而言,新冠病毒阳性个体中[某种细菌名称]合并感染的比例为19%。特别值得关注的是,在重症监护病房的合并感染中,六分之一归因于[某种细菌名称],这表明其对患者预后和医疗负担有重大影响。该研究强调了新冠病毒与[某种细菌名称]合并感染的惊人流行率,这可能会加剧患者的临床严重程度,并给治疗策略带来挑战。这些发现强调了在新冠疫情背景下进行警惕监测和有针对性干预以减轻细菌合并感染不利影响的重要性。